Donate - Поддержка фонда Ф.Б.Березина

Изяслав Лапин. Стресс. Тревога. Депрессия. Алкоголизм. Эпилепсия. 19

Список иноязычной литературы, A-L

Adams P. W., Folkard J., Wynn V. et al. Influence of oral contraceptives, pyridoxine (vitamin В 6), and tryptophan on carbohydrate metabolism. — Lancet. — 1976. April 10, — P. 759-764.

Alberati Giani D., Cesura A. M. Expression of the kynurenine enzymes in macrophages and microglial cells: regulation by immune modulators. — Amino Acids. — 1998. — V. 14. — P. 251-256.

Aldino C., Mazzari S., Toffano G et al. Effects of intracerebral quinolinic acid injections on serotonergic neurons. Clinical Neuropharmacology. — 1984. — V. 7. Suppl.l. — P. 454-455.

Allegri G. Costa C., De Antoni A. A further contribution to the choice of the dose for 1-tryptophan load test. — Acta vitamin, enzy-mol. (Milano). — 1978. — V. 32. — P. 163-166.

Allegri G., De Antoni A., Costa C. Non-enzymatic transamination between pyridoxal-5-phosphate and kynurenines in the presence of zinc ions. — Ital. J. Biochem. — 1971. — V. 20. — P. 139-142.

Altar C. A., Bennett B. L., Wallace R., Yuwiler A Corticosteroid induction of tryptophan oxygenase. Attenuation by intragastrically administered carbohydrates and metabolites. — Biochem. Pharmacol. — 1983. — V. 32. — P. 979-984.

Altman K, Greengard 0. Correlation of kynurenine excretion with liver tryptophan pyrrolase levels in disease and after hydrocortisone induction. — J. Clin. Invest. — 1966. — V.45. — P. 1527-1534.

Anton R. F., Becker H. C. Pharmacotherapy and pathophysiology of alcohol withdrawal. — The Pharmacology of Alcohol Abuse. Chapter 13. — Berlin. — Springer — 1995. — P. 315-367.

ArendtJ., Deacon S. Treatment of circadian rhythm disorders-melatonin. — Chronobiology Internat. — 1997. — V. 14. — P. 185-204.

Avallone R., Zeneroli M. L., Venturini I. et al. Endogenous ben-zodiazepine-like compounds and diazepam binding inhibitor in serum of patients with liver cirrosis with and without overt encephalopathy. — Gut. — 1998. — V. 42. — P. 461-468.

Axelrod J. An unexpected life in research. — Ann. Rev. Pharmacol. Toxicol. — 1988. -V. 28. — P. 1-23.

Badaway A. A.-B., Evans M. Tryptophan pyrrolase in ethanol administration and withdrawal. — Advances Exp. Biol. Med. -1973. -V. 35. — P. 105-123.

Badaway A. A-B., Evans M. The effects of ethanol on tryptophan pyrrolase activity and their comparison with those of phenobar-bitone and morphine. — Advances Exp. Biol. Med. — 1975. — V. 59. -P. 229-251.

Badaway А. А.-В., Evans М. Further evidence against inhibition of synthesis of rat liver tryptophan pyrrolase by chronic ethanol administration. — Brit. J. Alcohol and Alcoholism. — 1979. — V. 14. -P. 59-64.

Badaway А А.-В., Evans M. Inhibition of rat liver tryptophan pyrrolase activity and elevation of brain tryptophan concentration by acute administration of small doses of antidepressants. — Brit. J. Pharmacol. — 1982. — V. 77. — P. 59-67.

Badaway A. A-B., Evans M. Unsuitability of control sucrose or glucose in studies of the effects of chronic ethanol administration on brain 5-hydroxytryptamine metabolism. — J. of Pharmacol. Methods. — 1980. — V. 3. — P. 167-171.

Badaway A. A.-B., Evans M., Punjani N. F. Enhancement of rat brain metabolism of a tryptophan load by chronic ethanol administration. — Brit. J. Phramcol. — 1980. — V. 68. — P. 22-24.

Badaway A. A.-B., Punjani N. F., Evans M. Enhancement of rat brain tryptophan metabolism by chronic ethanol administration and possible involvement of decreased liver tryptophan pyrrolase activity. — Biochem. J. — 1979. — V. 178. — P. 575-580.

Badaway A. A-B., Punjani N. F., Evans С. M., Evans M. Inhibition of rat brain tryptophan metabolism by ethanol withdrawal and possible involvement of the enhanced liver tryptophan pyrrolase activity. — Biochem. J. — 1980. — V. 192. — P. 449-455.

Badaway A A-B., Rommelspacher H., Morgan C. J. Bradley D. M., Banner A., Ehlert A., Blum S., Spies C. D. Tryptophan metabolism in alcoholism. Tryptophan but not excitatory amino acid availability to the brain is increased before the appearance of the alco-holwithdrawal syndrome in man. Alcohol and alcoholism. — 1998. -V. 33. — P. 616-625.

Baker G. В., Chokka P. R., Bornstein R. A. Neurochemical and some related psychopharmacological aspects of Tourette's syndrome: an update (a review). — J. of Psychopharmacol. -1995. -V.9. -P. 273-280.

Bakker M. H.M., Foster A. C. An investigation of the mechanisms of delayed neurodegeneration caused by direct injection of quinolinate into the rat striatum in vivo. — Neurosci. -1991. — V. 42. -P. 387-395.

Baran H., Amann G., Lubec В., Lubec G. Kynurenic acid and kynurenine aminotransferase in heart. — Pediatric Res. — 1997. -V. 41. — P. 404-410.

Baran H., Gramer D., Honack D., Loscher W. Systemic administration of kainate induces marked increases of endogenous kynurenic acid in various brain regions and plasma in rats. — Eur. J. Pharmacol. — 1995. — V. 286. — P. 167-175.

Baran H., Hainfellner J. A., Keeplinger В., Mazal P. R., Schmid H., Budka H. Kynurenic acid metabolism in the brain of HIV-1 infected patients. — J. Neural Transm. — 2000. — V. 107. -P. 1127-138.

Baran H., Jellinger K, Deecke L. Kynurenine metabolism in Alzheimer disease. — J. Neural transmission. — 1999. — V. 106. — № 2. -P. 165-182.

Barchas J., Usdin E. (Eds.) Serotonin and Behavior. — Academic Press. — New York-London. — 1973. — 642 p.

Barrett J. E. The relationship of life events to the onset of neurotic disorders. — Stress and Mental Disorders (eds. Barrett J. E., Rose R M., Klerman G. L.) — Raven Press. — New York. — 1979. -1979. — P. 87-109.

Basile A S., Hughes R.D., Harrison P. M. et al. Elevated brain concentrations of 1,4-benzodiazepines in fluminant hepatic failure. -New England med. J. — 1991. — V. 325. — P. 473-481.

BazzettT. J., Becker J. В., Kaatz К W„ Albin R. L Chronic int-rastriatal dialytic administration of quinolinic acid produces selective neural degeneration. — Exper. Neurology. — 1993. — V. 120. -P. 177-185.

BazzettT. J., Falik R. C., Becker J. В., Albin R. L. Chronic intras-triatal administration of quinolinic acid produces transient nocturnal hypermotility in the rat. — Brain Res. Bull. — 1996. — V. 39. -P. 69-74.

Bazzett T. Geiger A., Coppola В., Albin R. The neuronal NOS inhibitor L-MIN, but not 7-NINA reduces neurotoxic effects of chronic intrastriatal administration of quinolinic acid. — Brain Res. -1997.-V. 775.-P. 229-232.

Beal M. F., Ferrante R J., Swartz K. J., Kowall N. W. Chronic quinolinic acid lesions in rats closely resemble Huntington's disease. — J. Neurosci. — 1991. — V. 11. — P. 1649-1659.

Beal M. F., Matson W. R, Swartz K. J., Gamache P. H., Bird E. D. Kynurenine pathway measurements in Huntington's disease: evidence for reduced formation of kynurenic acid. — J. Neuroche-mistry. — 1990. — V. 55. — P. 1327-1339.

Behan W. M. et al. Oxidative stress as a mechanism for quinolinic acid-induced hippocampal damage: protection by melatonin and deprenyl. — Br. J. Pharmacol. — 1999. — V. 128. — P. 754-760.

Benassi C. A., Benassi P., Allegri G., Ballarin P. Tryptophan metabolism in schizophrenic patients. — J. Neurochem. — 1971. -V. 7. — P. 264.

Benesova 0., Benes V. Brain acetylcholine, liver tryptophan pyrrolase and glycogen in rats selected for high and low activity and defectation rates. — Activ. Nerv. Super. — 1974. — V. 16. — P. 97-98.

Benesova 0., Benes V. The effect of maprotiline on brain serotonin metabolism in rats. — Activ. Nerv. Super. — 1974. -V. 16. -P. 190-191.

Beninger R J., Colton A M., Ingles J. L., Jhamandas K, Boe-gman R J. Picolinic acid blocks the neurotoxic but not the neuroex-citant properties of quinolinic acid in the rat brain: evidence for turning behavior and tyrosine hydroxilase immunochemistry. — Neu-roscience. — 1994. — V. 61. — P. 603-612.

Beninger R. J., Jhamandas K., Boegman R. J., El-Defrawy S. R Kynurenic acid-induced protection of neurochemical and behavioral deficits produced by quinolinic acid injections into the nucleus basalis of rats. — Neurosci. Lett. — 1986. — V. 68. — P. 317-321.

Bermond P. Therapy of side effects of oral contraceptive agents with vitamin B6. — Acta vitamin, enzymol. (Milano). — 1982. — V. 4. -P. 45-54.

Beskid M. Effect of quinolinic acid administered during pregnancy on the brain of offspring. Exp. and toxicol. Pathol. — 1994. -V. 46. — P. 323-328.

Beskid M. Toxic effect of quinolinic acid administered during pregnancy on the cerebral cortex of rat's offspring: an ultrastructu-ral study. — Exp. and toxicol. Pathology. -1994. -V. 46. — P. 397-402.

Bespalov A, Dumpis M., Piotrovsky L., Zvartau E. Excitatory amino acid antagonist kynurenic acid attenuates rewarding potential of morphine. — Eur. J. Pharmacol. — 1994. — V. 264. — P. 233-240.

Bevan M. D., Brotchie J. M., Crossman A R. Intracerebral injections of the EAA antagonist kynurenate in the entopeduncular nucleus of the rat elicits a range of hyperkinetic disorders. — Eur. J. Pharmacol. — 1990. -V. 183. — P. 943.

Bhattacharya S. K, Rao P. J.R.M., Sen A. P. Anxiogenic activity of intracerebroventricularly administered bradykinin in rats. -J. Psychopharmacology. — 1995. — V. 9. — P. 348-354.

Bird S. J., Parlee M. B. Of mice and men (and women and children) : scientific and ethical implications of animal models. — Progress in Neuro-psychopharmacology and biological psychiatry. — 2000. -V. 24. — P. 1219-1228.

Birkley S., Collins J. F., Perkins M. N. et al. The effects of cyclic dicarboxylic acids on spontaneous and amino acid-evoked activity of rat cortical neurons. — Brit. J. Pharmacol. 1982. — V. 77. — P. 7-12.

Blight A. R., Cohen Т. I., Saito K, Heyes M. P. Quinolinic acid accumulation and functional deficits following experimental spinal cord injury. — Brain. — 1995. — V. 118. — P. 101-117.

Blight A. R., Saito К, Heyes M. P. Increased levels of the excito-toxin quinolinic acid in spinal cord following contusion injury. — Brain Res. — 1993. — V. 632. — P. 314-316.

Bockermann R, Reiser M., Wolf G. Potassium-stimulated taurine release and nitric oxide synthase activity during quinolinic acid lesion of the rat striatum. — Neurochem. Res. — 1998. — V. 23. -P. 469-477.

Boegman R. J., Metcalf R, Riopelle R J., Ludwin S. K. Neurotoxicity of quinolinate in the rat nucleus basalis magnocellularis. -Brain Res. — 1987. — V. 417. — P. 315-320.

Bougeois B. F.D., Dodson W. E., Ferrendelli J. A. Potentiation of the antiepileptic activity of phenobarbital by nicotinamide. — Epilepsia. — 1983. — V. 24. — P. 238-244.

Bradshaw С. M., Stoker M. J., Szabadi E. The effect of microe-lectrophoretically applied clonidine on single cerebral cortical neurons in the rat. Evidence for interaction with al-adrenoreceptors. -Naunyn-Schmiedebergs Arch. Pharmacol. — 1982. — V. 320. -P. 230-234.

Brambilla F., Bellodi L., Giampaolo P. et al. Psychoimmunolo-gical aspects in anxiety disorders. XXIst CINP Congress (Glasgow, July 12-16,1998). — 1998. — Final Programme. P. 195.

Bremner J. D., Innis R В., Southwick S. M., Staib L., Zoghbi S., Charney D. S. Decreased benzodiazepine receptor binding in prefrontal cortex in combat-related posttraumatic stress disorder. -Amer. J. Psychiatry. — 2000. — V. 157. — P. 1120-1126.

Brett R R, Pratt J. A. Chronic handling modifies the anxiolytic effect of diazepam in the elevated plus-maze. — Eur. J. Pharmacol. -1990.-V. 178.-P. 135-138.

Brew B. J., Corbell J., Oemberton L., Evans L et al. Quinolinic acid production is related to macrophage tropic isolates of HIV-1. -J. Neurovirology. — 1995. — V. 1. — P.369-374.

Brooks P. A., Smith D. A, Stone T. W„ Kelly J. Postsynaptic action of kynurenic acid in the rat dentate gyrus. — Neurosci. Lett. -1986.-V. 66.-P. 96-100.

Brouwers S. P., Heyes M. P., Moss H. A, Wolters P. L., Po-plack D. G., Markey S. P. Quinolinic acid in the cerebrospinal fluid of children with symptomatic human immunodeficiency Virus 1 disease: relationships to clinical status and therapeutic response. -J. Infect. Dis. — 1993. — V. 168. — P. 1380-1386.

Brzezinski A. Melatonin in humans. — The New England J. Medicine. — 1997. — V. 336. — P. 186-195.

Bueno J. R., Himwich H. E. A dualistic approach to some biochemical problems of endogenous depressions. — Psychosomatics. -1967.-V. 8.-P. 82-94.

Bye A. M. Prolactin and seizure activity. — Arch. Dis. Child. -1985.-V. 60.-P. 848-851.

Cabibbe F., Paracchi G. L'attivita 3-idrossi-chinureninasica e triptofano-pirrolasica in ratti trattati con farmaci neurolettici ed anti-depressivi. — Boll. Soc. ital. biol. sperim. — 1968. — V. 44. -P. 1254-1258.

Calderon S. F., Sanberg P. R., Norman A. B. Quinolinic acid lesions of rat striatum abolish D1 and D2-dopamine receptor-media-ted catalepsy. — Brain Res. — 1988. — V. 450. — P. 403-407.

Canal N., Maffei-Faccioli A. Induction of tryptophan-peroxyda-se-oxydase in rat liver by reserpine. — Naturwissenschaften. -1959. -Bd. 46. — S. 494.

Carpenedo R, Chiarugi A., Russi P. et al. Inhibitors of kynurenine hydroxylase and kynureninase increase cerebral formation of kynurenate and have sedative and anticonvulsant activities. — Neu-roscience. — 1994. -V. 61. — P. 237-244.

Carredu P. Veranderungen des Tryptophan-stoffwechsels den Blitz-Nick-Salaam-Krampfen des Kindesalters. — Helv. paediatr.acta. -1963.-V. 18.-P. 398-407.

Cassidy F., Murry E., Carroll B. J. Tryptophan depletion in recently manic patients treated with lithium. — Biol. Psychiatry. -1998. -V. 43. — P. 230-232.

Cazzullo C. L., Bozzoli A., Freni S., Mangoni A. Metabolic and clinical parameters in affective illness.- Psychopharmacologia. -1972. — V. 26 Suppl. — P. 64-69.

Cazzullo C. L., Sachetti E., Smeraldi E. N-methylnicotinamide excretion and affective disorders. Psychological Medicine. -1976. -V. 6. — P. 265-270.

Charlton К G., Johnson T. D., Hamed А. Т., Clarke D. E. Cardiovascular actions of kynuramine and 5-hydroxykynuramine in pithed rats. — J. Neural Transmission. — 1983. — V. 57. — P. 199-211.

Charlton K. G„ JohnsonT. D., Maurice R. W., Clarke D. E. Kynuramine: high affinity for 3H-tryptamine binding sites. — Eur. J. Pharmacol. — 1984. — V. 106. — P. 661-664.

Chen C., Kalucy R. S., Olulode I. et al. Plasma tryptophan and sleep. — Sleep. — Fischer. — Basel. — 1975. — P. 482-486.

Chiancone F. M. Ghiandole endocrine e metabolismo triptofa-no -> acido nicotinico. — Acta viatminologica. — 1962. — V. 70. -P. 49-60

Chiancone F. M. И metabolismo triptofano — acido nicotinico nelle malattie psichiatriche. — Acta viatminol. enzymol. — 1968. -V.22.-P. 111-113.

Chiancone F. M. Variazioni in senso opposito della triprofano pirrolasi e della 3-OH-antranilico ossidasi dopo un carico di triptofano. Acta vitaminologica et enzymologica. 1978. — A. 32. — № 5-6. -P. 150-154.

Chaincone F. M., Ginoulhiac E., Tenconi L. Т., Bonomi U. Studio per la dimostrazione della triptofanpirrolasi epatica nell'uomo. -Acta vitaminologia. — 1966. — V. 20. — P. 225-234.

Charney D. Psychological stress alters brain structure and function: implications for the pathophysiology of PTSD. XXIst CINP Congress (Glasgow, July 1998). — Abtracts. — P. 33.

Chiarugi A., Carpenedo R. Molina M. T. et al. Comparison of the neurochemical and behavioral effects resulting from the inhibition of kynurenine hydroxylase and kynureninase. — J. Neurochem. -1995.-V. 65.-P. 1176-1183.

Chiarugi A, Carpenedo R, Moroni F. Kynurenine disposition in blood and brain of mice: effects of selective inhibitors of kynurenine hydroxilase and kynureninase. — J. Neurochem. — 1996. -V. 67. -P. 692-698.

Cho-Chung Y. S., Pitot H. C. Feedback control of rat liver tryptophan pyrrolase. I End product inhibition of tryptophan pyrrolase activity. — J. Biol. Chem. — 1967. — Y. 242. — P. 1192-1198.

Chrousos G. P., McCarty R, Pacak K., Cizza G., Sternberg E., Gold P. W., Kvetnansky R. (eds.) Stress. Basic Mechanisms and Clinical Implications. Annals of the New York Academy of Sciences. -1995.-V. 771.-755 p.

Chuang D. M. Lithium as a neuroprotective drug in vivo and in vitro: mechanisms and implications. — The Intern. J. Neuropsychop-harmacol. — 2000. — V. 3. — Suppl. 1. — S. 11.

Coleman P. A., Massey S. C., Miller R. F. Kynurenic acid distinguishes kainate and quisqualate receptors in the vertebrate retina. -Brain Res. — 1986. — Y. 381. — P.172-175.

Collingridge G. L., Lester R.A. J. Excitatory amino acids receptors in the vertebrate central nervous system. — Pharmacol. Reviews. — 189. — V. 40. — 145-210.

Collins J. F., Connick J. H., Stone T. W. Absense of uptake of and binding of radiolabeled quinolinic acid in rat brain. Brit. J. Pharmacol. — 1985. — V. 85. — 373P.

Collins W. С. Plasma prolactin concentration following epileptic and pseudoseizures. J. Neurol. Neurosurg. Psychiatr. -1983. -V. 46. — P. 505-508.

Coloma F. M., Niles N. P. Melatonin enhancement of [3H] -gamma-aminobutyric acid and [3H] muscimol binding in rat brain. -Biochem. Pharmacol. — 1988. — V. 37. — P. 1271-1274.

Colombo L. L., Chen G.-L., Lopez M. C., Watson R R Melatonin induced increase in gamma-interferon production by murine splenocytes. — Immunol. Lett. — 1992. -V. 33. — P. 123-126.

Connick J. H., Stone T. W. The effect of quinolinic acid and the kynurenines on the uptake of [3H] — D-aspartate in rat brain. — Brit. J. Pharmacol. — 1985. — V. 84. — 92P.

Cook B. L., Winokur G., Garvey M. J., Beach V. Depression and previous alcoholism in the elderly. — Brit. J. Psychiatry — 1991. -V. 58. — P. 72-75.

Coppen A, Wood К 5-hydroxytryptamine in the pathogenesis of affective disorders. — Serotonin in Biological Psychiatry (Advances in Biochemical Psychopharmacology, V.34). — Raven Press. -New York. — 1982. — P. 249-258.

Cooper B. R, Viik K., Ferris R, White H. L. A role for GABA in audiogenic seizures during alcohol withdrawal. — Brain Rs. Bull. -1980. — V. 5. — Suppl. 2. — P. 815-819.

Come S. J., Pickering R W., Warner R T. A method for assessing the effect of drugs on the central actions of 5-hydroxytryptamine. — Brit. J. Pharmacol. — 1963. — V. 20. — P. 106-120.

Costa C., Bettero A, Allegri G. Rapid determination of tryptophan and its metabolites along the kynurenine pathway by HPLC. -Progress in Tryptophan and Serotonin Research. Berlin-New York. -1984. — P. 67-70.

Crawley J. N. Neuropharmacology specificity of a simple animal model for the behavioral actions of benzodiazepines. — Pharmacol. Biochem. Behav. — 1981. — V.15. — P. 695-699.

Crawley J. N., Davis L. G. Baseline exploratory activity predicts anxiolytic responsiveness to diazepam in five mouse strains. — Brain Res. Bull. — 1982. — V. 8. — P. 609-612.

Crawley J. N., Skolnik P., Paul S. M. Absence of intrinsic antagonist actions of benzodiazepine antagonists on an exploratory model of anxiety in the mouse. — Neuropharmacology. -1984. -V. 23. -P. 531-537.

Criswell H. E., Johnson К. В., Mueller R. A, Breese G. R. Evidence for involvement of brain dopamine and other mechanisms in the behavioral action of the N-methyl-D-aspartic acid antagonist MK-801 in control and 6-hydroxydopamine-lesioned rats. — J. Pharmacol. exp. Ther. — 1993. — V. 265. — P. 1001-1010.

Cruz A. P., Frei F., Graeff F. G. Ethopharmacological analysis of rat behavior on the elevated plus-maze. — Pharmacol. Biochem. Behav. — 1994. — V. 49. — P. 171-176.

Curras M. C., Dingledine R Selectivity of amino acid transmitters acting at N-Methyl-D-aspartate and Amino-3-hydroxy-5-methyl-4-isoxa-zolepropionate receptors — Molecular Pharmacol. — 1992. — V. 41. -P. 520-526.

Curzon G., Bridges P. К Tryptophan metabolism in depression. -J. Neurol. Neurosurg. Psychiat. — 1970. — V.33. — P. 698-704.

Curzon G., Green A R Rat liver tryptophan pyrrolase activity and brain 5-hydroxytryptamine. — Biochem. J. -1969. — V. 111. -15 P.

Czuczwar S., Kleinrok Z. Convulsive threshold in the maximal electroshock in mice. Role of dopamine and gamma-aminobutyric acid. — 2nd Regional Conference on Epilepsy. — Abstr. — № 7, 48. -Warszawa. 1978.

Czuczwar S. J., Meldrum B. Protection against chemically induced seizures by 2-amino-7-phosphonoheptanoic acid. — Eur. J. Pharmacol. — 1982. -V. 83. — P. 335-338.

Dalvi A, Lucki I. Murine models of depression. — Psychophar-macology. — 1999. -V. 147. — P. 17-19.

Dantzer R Behavioral effects of cytokines. XXIst CINP Congress (Glasgow, July 12-16,1998). 1998. — P. 169.

Davis B. A, Boulton A. A The trace amines and their acidic metabolites in depression-An overview. — Progress in Neuro-Psychop-harmacology and Biological Psychiatry. — 1994. — V. 18. — P. 17-46.

Dawson G. R, Tricklebank M. D. Use of the elevated plus maze in the search for novel anxiolytic agents. — 1995. — V. 16. — P. 33-36.

DeBattista C., Posener J. A., Kalehzan В. M., Schatzberg A. F. Acute antidepressant effects of intravenous hydrocortisone and CRH in depressed patients: a double-blind, placebo-controlled study. — Amer. J. Psychiatry. — 2000. — V. 157. — P. 1334-1337.

DeBellis M. D., Keshavan M. S„ Spencer B. S., Hall J. N-acety-laspartate concentration in the anterior cingulate of maltreated children and adolescents with PTSD. — Amer. J. Psychiatry. — 2000. -V.157.-P. 1175-1177.

Delgado P. L., Charney D. S., Price H. et al. Serotonin function and the mechanism of antidepressant action: Reversal of antidepres-sant-induced remission by rapid depletion of plasma tryptophan. -Arch. Gen. Psychiatry. — 1990. — V. 47. — P. 411-418.

De Marco P., Zagnoni P. Allopurinol and severe epilepsy. — Neurology. — 1986. — V. 36. — P. 1538-1539.

Di Chiara G., Gessa G. L. (Eds.) Glutamate as a Neurotransmitter. Advances in Biochemical Psychopharmacology. — V. 27. — Raven Press. — New York. — 1981. — 445 p.

Dailey J. W„ Mishra P. К., Ко К. H„ Penny J. E„ Jobe P. C. Serotonergic abnormalities in the central nervous system of seizure-naive genetically epilepsy-prone rats. — Life Sci. -1991. -V. 50. -P. 319-326.

De Marco P. How to use Allopurinol in severe epliepsy. Epilepsia. — 1991. — V. 32. — Suppl. 1. — P. 97.

Dilman V. M., Lapin I. P., Oxenkrug G. F. Serotonin and Aging. -In: Serotonin in Health and Disease (ed. Essman W. В.) V. 5: Clinical

Applications. Chapter 4. — SP Medical and Scientific Books. — New York-London. — 1979. — P. 111-212.

Dingledine R., McBain C. J., McNamaraJ. O. Excitatory amino acid receptors and epilepsy. — Trends in Pharmacol. Sci. — 1990. -V. 11. — P. 334-338.

Dobbie M. S., Surtees R A. H. Concentrations of quinolinic acid in cerebrospinal fluid measured by gas chromatography and electron-impact ionization mass spectrometry — age-related changes in a paediatric reference population. — J. Chromatography. -1997.-V. 696.-P. 53-58.

Dolin S. J., Halsey M. J., little H. J. — Calcium channel antagonists decrease the ethanol withdrawal syndrome. — Brit. J. Pharmacol. — 1986. — V. 87. — P.47P.

Dsarathy S., Mullen K. D. Benzodiazepines in hepatic encephalopathy: sleeping with the enemy. — Gut. — 1998. — V. 42. -P. 764-765.

Du F. Kynurenine pathway eznymes in a rat model of chronic epilepsy: immunochemical study of activated glial cells. — Neurosci-ence. — 1993. — V. 55. — P. 975-989.

Du F., Okuno E., Whetell W. 0., Kohler C., Schwarcz R. Immu-nohistochemical localization of quinolinic acid phosphoribosyltran-sferase in the human neostriatum. — Neurosci. — 1991. — V. 42. -P. 397-406.

Dubokovic M. L. Melatonin receptors in the central nervous system. — Kynurenine and Serotonin Pathways (Eds. Schwarcz R, Young S. N.. Brown S. N.). — Plenum Press. New York. — 1991. -P. 255-265.

Dunn A J. Effects of cytokines on cerebral neurotransmitter metabolism and function. XXIst CINP Congress (Glasgow, July 12-16,1998). — 1998. — P. 169.

During М. J., Freese A., Heyes M. P. et al. Neuroactive metabolites of ^tryptophan, serotonin and quinolinic acid, in striatal extracellular fluid. Effect of tryptophan loading. — FEBS Lett. — 1989. -V. 247. — P. 438-444.

Dursun S. M., Farrar G., Handley S. L. et al. Elevated plasma kynurenine in Tourette syndrome. J. Neurosci. Res. — 1994. — V. 37. -P. 55-60.

Eastman C. L., GuilarteT. R. Cytotoxicity of 3-hydroxykynure-nine in a neuronal hybrid cell line. Brain Research. -1989. — V. 495. -P. 225-231.

Eastman C. L., Urbanska E., Love A., Kristensson K., Schwarcz R Increased brain quinolinic acid production in mice infected with a hamster neurotropic measles virus. — Exper. Neurol. — 1994. -V. 125. — P. 119-124.

Eichler O., Farah A (eds.) Handbuch der experimentellen Phar-makologie. — V. 19: 5-hydroxytryptamine and related indolalkylami-nes. — Springer. — Berlin-Heidelberg-New York. — 1966.

Elias P. K., Redgate E. Effects of immobilization stress on open field behavior and plasma corticosterone levels of aging C57B1/6J mice. — Exper. Aging Research. — 1975. — V.l. — P. 127-135.

Ellen S. R, Morris P.-L.-P., Olver J. S., Reutens D. ey al. Positron emission tomography study of benzodiazepine receptors in post-traumatic stress disorder. — Int. J. Neuropsychopharmacol. -2000. — V. 3. — Suppl. 1. — S. 277.

Ellenbogen M. A, Young S. N., Dean P. et al. Mood response to acute tryptophan depletion in healthy volunteers: sex differences and temporal stability. — Neuropsychopharmacology. — 1996. -V. 15. — P. 465-474.

Elmslie K. S., Yoshikami D. Effects of kynurenate on root potentials evoked by synaptic acitivty and amino acids in the frog spinal cord. — Brain Res. — 1985. — V. 330. — P. 265-272.

Espey M. G., Chernyshev 0. N., Reinhard J. F., Namboodi-ri M. A.A., Colton C. A. Activated human microglia produce the exci-totoxin quinolinic acid. — Neuroreport. — 1997. — V. 8. — P. 431-434.

Espey M. G., Tang Y., Morse H. C., Moffett J. R, Namboodi-ri M.A A. Localization of quinolinic acid in the murine AIDS model of retrovirus-induced immunodeficiency: implications of neurotoxicity and dendritic cell immunopathogenesis. — AIDS. — 1996. — V. 10. -P. 151-153.

Fauteck J. D., Bockmann J., Bockers Т. M., Wittkowski W., Kohling R, Lucke A, Straub H., Speckmann E. J., Tuxhorn I., Wolf P. Melatonin reduces low-Mg2+ epileptiform activity in human temporal slices. — Exp. Brain Res. — 1995. — V. 107. — P. 321-325.

Fernando J. C., Joseph M. H., Curzon G. Tryptophan plus a pyrrolase inhibitor for depression. — Lancet. -1975. — V.l. — No. 7899. -P. 171.

Feske U., Frank E., Mallinger A. G., Houck P. R, Fagiolini A., Shear M. K., Grochocinski V.J., Kupfer D. J. Anxiety as a correlate of response to the acute treament of bipolar I disorder. — Amer. J. Psychiatry. — 2000. — V. 157. — P. 956-962.

File S. E. The use of social interaction test as a method for detecting anxiolytic activity of chlordiazepoxide-like drugs. — J. Neu-rosci. Methods. — 1980. — V. 2. — P. 219-238.

Finn S. F„ Hyman В. Т., Storey E„ Miller J. M„ Beal M. F. Effects of aging on quinolinic acid lesions in rat striatum. Brain Res. -1991.-V. 562.-P. 276-280.

Flanagan E. M., Erickson J. В., Viveros О. H., ChangS. Y., Rein-hard J. F. Neurotoxin quinolinic acid is selectively elevated in spinal cord of rats with experimental allergic encephalomyelitis. — J. Neurochem. — 1995. -V. 64. — P. 1192-1196.

Foldes A., Costa E. Relationship of brain monoamine and locomotor acitivity in rats. — Biochem. Pharmacol. — 1975. — V.24. -P. 1617-1621.

Foster А. С., Collins J. F., Schwarcz R. On the excitotoxic properties of quinolinic acid, 2,3-piperisine dicarboxylic acids and structurally related compounds. — Neuropharmacology. -1983. — V. 22. -P. 1331-1342.

Foster A. C„ Miller L. P., OldendorfW. H., Schwarcz R. Studies on the disposition of quinolinic acid after intracerebral or systemic administration in the rat. — Exper. Neurol. — 1984. — V. 84. -P. 428-440.

Foster A C., Okuno E., Brougher D.S. etal. A radioenzymatic assay for quinolinic acid. — Analytical Biochemistry. — 1986. — V. 158. -P. 98-103.

Foster A C., Vezzani A., French E. D., Schwarcz R. Kynurenic acid blocks neurotoxicity and seizures induced in rats by the related brain metabolite quinolinic acid. — Neurosci. Lett. — 1984. -V. 48. -P. 273-278.

Foster A C., Whetsel W. 0., Bird E., Schwarcz R. Quinolinic acid phosphoribosyltransferase in human and rat brain: activity in Huntington's disease and in quinolinate-lesioned rat striatum. — Brain Res. — 1985. — V. 336. — P. 207-214.

Foster A. C., White R. J., Schwarcz R. Synthesis of quinolinic acid by 3-hydroxyanthranilic acid oxygenase in rat brain tissue in vitro. — J. Neurochemistry. — 1986. — V. 47. — P. 23-30.

Frazer A., Pandey G. N., Mendels J. Metabolism of tryptophan in depressive disease. — Acrh. Gen. Psychiatry. — 1973. -V. 29. -P. 528-535.

Fredholm В. В., Battig K., Holmen J., Nehlig A., Zvartau E. E. Actions of caffeine in the brain with special reference to factors that contribute to its widespred use. — Pharmacol. Revs. -1999. -V. 51. — P. 83-133.

French E. D., Foster A C., Vezzani A, Schwarcz R. Quinolinate and kynurenate, two endogenous tryptophan metabolites with potential links to epileptic disorders. Clin. Neuropharmacology. -1984.-V. 7.-P. 456-457.

Frieden E., Westmark G. W., Schor J. M. Inhibition of tryptophan pyrrolase by serotonin, epinephrine and tryptophan analogs. -Arch. Biochem. Biophysics. — 1961. — V. 92. — P. 176-182.

Friedman M. J., Krstulovic A. M., Severinghaus J. M., Brown S. J. Altered conversion of tryptophan to kynurenine in newly abstinent alcoholics. — Biol.Psychiatry. — 1988. — V. 23. — P. 89-93.

Fujiwara M., Shibata M., Watanabe Y. et al. Indoleamine 2,3-dio-xygenase. Formation of 1-kynurenine from 1-tryptophan in cultured rabbit pineal gland. — J. Biol. Chemistry. 1978. — V. 253. — P. 6081-6085.

Fukuuj S., Schwarcz R., Rapport S. I., Takada Y., Smith Q. R. Blood-brain barrier transport of kynurenines: implications for brain synthesis and metabolism. — J. of Neurochemistry. -1991. — V. 56. — P. 2007- 20017.

Furtado J. C.S., Mazurek M. F. Behavioral characterization of quinolinate-induced lesions of the medial striatum: relevance for Huntington disease. — Developmental Medicine and Child Neurology. — 1996. — V. 38. — P. 158-168.

Gal E. M. Cerebral tryptophan-2,3-dioxygenase (pyrrolase) and its induction in rat brain. — J. Neurochem. — 1974. — V. 22. -P.861-863.

Gal E. M., Sherman A. D. Synthesis and metabolism of 1-kynu-renine in rat brain. J. Neurochemistry. -1978. — V. 30. — P. 607-613.

Gal E. M., Sherman A. D. L-kynurenine. Its synthesis and possible regulatory function in brain (overview). — Neurochemical Res. — 1980. — V. 5. — P. 223-239.

Gal E. M.( Young R. В., Sherman A. D. Tryptophan loading: consequent effects on the synthesis of kynurenine and 5-hydroxyin-doles in rat brain. — J. Neurochem. — 1978. — V. 31. — P. 237-244.

Ganong A. H., LanthornT. H., Cotman C. W. Kynurenic acid inhibits synaptic and acidic amino acid-induced responses in the rat hippocampus and spinal cord. — Brain Res. — 1983. — V. 273. -P. 170-174.

Geller Е., Yuwiler A, Shapiro S. Comparative effects of a stress and Cortisol upon some enzymes activities. — Biochimica Biophysica Acta. — 1964. — V. 93. — P. 311-315.

Genefke I. K., Halter D., Dreux C. Effets du Cortisol sur l'elimi-nation urinaire des hydroxyindols et la cynurenine. — Clin. chim. acta. — 1969. — V. 24. — P. 239-245.

Genis P., Jett M., Bernton E. W. et al. Cytokines and arachido-nic acid metabolites produced during human immunodeficiency virus (HIV)-infected macrophage-astrocyte interactions: implications for the neuropathogenesis of HIV disease. — J. exp. Med. — 1992. -V. 176. — P. 1703-1718.

Ghribi 0., Callebert J., Plotkine M., Boulu R. G. Effect of kynurenic acid on the ischemia-induced accumulation of glutamate in the rat striatum. — Neuroreport. — 1994. — V. 5. — P. 435-437.

Gilka L. Schizophrenia. A Disorder of Tryptophan Metabolism. -Acta Psychiatrica Scandinavica. — 1975. — V. 258 Suppl. — 83 p.

Goenjian A K, Steinberg A M., Najarian L. M., Fairbanks L. A, Tashjian M., Pynoos R. S. Prospective study of posttraumatic stress, anxiety, and depressive reactions after earthquake and political violence. — Amer. J. Psychiatry. — 2000. — V. 157. — P. 911-916.

Gould S. E., Handley S. L. Dose-dependent dual action of kynurenine, a tryptophan metabolite, on the turnover of 5-hydroxytrypta-mine. Brit. J. Pharmacol. — 1978. — V. 63. — P. 392P.

Gould S., Handley S. L. The uptake of kynurenine, a tryptophan metabolite, into mouse brain. — Brit. J. Pharmacol. — 1979. — V. 66. -P. 484-485.

Gramsberger J. B.P., Hodgkins P. S., Rassoulpour A. et al. Brain-specific modulation of kynurenic acid synthesis in the rat. — J. Ne-urochem. — 1997. — V. 69. — P. 290-298.

Grant К A. Animal models of the alcohol addiction process. -The pharmacology of Alcohol Abuse (ed. Kranzler H. R.). — 1995. -Chapter 9. — Berlin. — Springer. — P. 185-229.

Green A. R. Liver and brain tryptophan metabolism following hydrocortisone administration to rats and gerbils. — Brit. J. Pharmacol. — 1975. — V. 53. — P. 287-292.

Green A R, Aronson J. K. Metabolism of an oral tryptophan load. II Effect of pretreatment with the putative tryptophan pyrrolase inhibitors nicotinamide or allopurinol. — Brit. J. Clin. Pharmacol. -1980.-V. 10.-P. 611-615.

Green A R, Curzon G. The effect of tryptophan metabolites on brain 5-hydroxytryptamine metabolism. Biochemical Pharmacology. — 1970. — V. 19. — P. 2061-2068.

Green A. R, Curzon G. Effects of hydrocortisone and immobilization on tryptophan metabolism in brain and liver of rats of different ages. — Biochem. Pharmacol. — 1975. — V. 24. — P. 713-716.

Guidetti P., Eastman C. L., Schwarcz R. Metabolism of [5-H3] kynurenine in the rat brain in vivo: evidence for the existence of a functional kynurenine pathway. — J. Neurochem. -1995. — V. 65. -P. 2621-2632.

Guilarte T. R, Block L. D., Wagner H. N. The putative endogenous convulsant 3-hydroxykynurenine decrease benzodiazepine receptor binding affinity: implications to seizures associated with neonatal vitamin B6 deficiency. — Pharmacol. Biochem. Behav. -1988. -V. 30. — P. 665-668.

Guilarte T. R, Wagner H. N. Increased concentration of 3-hydroxykynurenine in vitamin B6 deficient neonatal rat brain. J. Neurochemistry. — 1987. — V. 49. — P. 1918-1926.

Guo Q., Kuang P. G. Hippocampal quinolinic acid concentrations in epileptogenesis in rats — Acata pharmacologica sin. — 1995. -V. 16. — P. 438-440.

Gyorgy L. Role of dopaminergic and GABA-ergic interactions in seizure susceptibility. — Arch, int pharmacodyn. -1979. — V. 241. —P. 280-286.

Haleem D. J., Yasmeen A., Parveen Т., Zafar A. Enhancement of hepatic tryptophan pyrrolase activity and decreases of open field locomotion following single and repeated administration of high doses of caffeine in rats. — Life Sciences. — 1994. — V. 54. — V. 17. -P. 297-304.

Halperin J. J., Heyes M. P. Neuroactive kynurenines in Lyme borreliosis. — Neurology. — 1992. — V. 42. — P. 43-50.

Handley S. L, Mc Blane J. W. An assessment of the elevated X-maze for studying anxiety and anxiety-modulating drugs. -J. Pharmacol. Methods. — 1993. — V. 29. — P. 129-138.

Handley S. L., Dursun S. M. Serotonin and Tourette's syndrome: movements such as head-shakes and wet dog-shakes may model human tics. — Advances Biosci. — 1992. — V. 85. — P. 235-253.

Handley S. L., Miskin R. C. The interaction of some kynurenine pathway metabolites with 5-hydroxytryptophan and 5-hydroxytryp-tamine. Psychopharmacology. — 1977. -V. 51. — P. 305-309.

Hankins M. W., Ruddock К. H. Neuropharmacology actions of kynurenic and quinolinic acids on horizontal cells of the isolated fish retina. — Brain Res. — 1986. — V. 380. — P. 297-302.

Harro J., Vasar E., Bradwejn J. CCK in animal and human research in psychiatry. — Trends in Pharmacol. Sci. — 1993. — Y. 14. -P. 244-249.

Haskovec L., Dostal J., Jirak R. The action of allopurinol as an inhibitor of liver tryptophan pyrrolase in depressions. — Activ. nerv. super. — 1972. — V. 14. — P. 131-132.

Hayaishi O. Indolamine 2,3-dioxygenase. A new vista in tryptophan metabolism. — Acta Vitaminol. Enzymol. (Milano). — 1975. -V. 29. — P. 17-20.

Hayaishi O., Hirata F., Fuijwara M. et al. Indoleamine 2,3-dioxy-genase. Note II. Biological function. — Acta vitaminol. enzymol. (Milano). — 1975. -V. 29. — P. 291-293.

Hankins M. W., Ruddock К. H. Neuropharmacological actions of kynurenic and quinolinic acids on horizontal cells of the isolated fish retina.- Brain Res. — 1986. — V. 280. — P. 297-302.

Harris C. A, Mirabda A. F., Tanguay J. J. et al. Modulation of striatal quinolinate neurotoxicity by elevation of endogenous brain kynurenic acid. — Brit. J. Pharmacol. — 1998. — V. 124. — P. 391-399.

Haug L. S., Ostvold A C., Totgner I. et al. Intracerebroventricu-lar administration of quinolinic acid induces a selective decrease of inositol (l,4,5)-triphosphate receptor in rat brain. — Neurochemistry International. — 1998. — V. 33. — P. 109-120.

Heinmets F. Computer simulation and analysis of tryptophan metabolism via kynurenine pathway in liver. — Computer Biol, and Med. — 1971. — V. 1. — P. 323-336.

Herve C., Beyne P., Jamault H., Delacoux E. Determination of tryptophan and its kynurenine pathway metabolites in human serum by high-performance liquid chromatography with simultaneous ultraviolet and fluorimetric detection. — J. Chromatography. -1996.-V. 675.-P. 157-161.

Heyes M. P. Potential mechanisms of neurologic disease in HIV infection. Chapter 138. Psychopharmacology. The Fourth Generation of Progress (ed. Bloom F., Kupfer D. J.) — Raven Press. -New York.-1995.-P. 1-7.

Heyes M. P., Achim C. L., Wiley C. A. et al. Human microglia converts Lrtryptophan into neurotoxin quinolinic acid. — Biochem. J. -1996. — V. 320. — Part 2. — P. 595-614.

Heyes M. P., Brew B. J., Martin A. et al. Quinolinic acid in cerebrospinal fluid and serum in HIV-1 infection: relationship to clinical and neurological status. — Ann. Neurol. 1991. — V. 29. -P. 202-209.

Heyes M. P., Lackner A Increased cerebrospinal fluid quinolinic acid, kynurenic acid and 1-kynurenine in acute septicemia. -J. Neurochem. — 1990. — V. 55. — P. 338-341.

Heyes М. P., Markey S. P. Quantification of quinolinic acid in rat brain, whole brain and plasma by gas chromatography and negative chemical ionization mass — spectrometry: effects of systemic 1-tryptophan administration on brain and blood quinolinic acid concentration. — Anal. Biochem. — 1988. — V. 174. — P. 349-359.

Heyes M. P., Mefford I. N., Quearry B. J., Dedhia M., Lackner A. Increased ratio of quinolinic acid to kynurenic acid in cerebrospinal fluid of D retrovirus-infected Rhesus macaques: relationship to clinical and viral status. — Ann. Neurol. -1990. — V. 27. — P. 666-675.

Heyes M. P., Morrison P. F. Quantification of local de novo synthesis versus blood contributions to quinolinic acid concentrations in brain and sysemic tissue. — J. Neurochem. — 1997. -V. 68.-P. 280-288.

Heyes M. P., Papagapiou M., Leonard C., Markey S. P., Auer R. N. Brain and plasma quinolinic acid in profound insulin-induced hypoglycemia. — J. Neurochemistry. — 1990. -V. 54. — P. 1027-1033.

Heyes M. P., Quearry B. J. Quantification of 3-hydroxykynure-nine in brain by high pressure liquid chromatography and electrochemical detection. J. Chromatography. — 1988. -V. 428. -P. 340-344.

Heyes M. P., Quearry B. J. Quantification of kynurenic acid in cerebrospinal fluid: Effects of systemic and central L-kynurenine administration. -J. Chromatogr. — 1990. — V. 530. — P. 108-115.

Heyes M. P., Quearry B. J., Markey S. P. Systemic endotoxin increases ^tryptophan, 5-hydroxyindolacetic acid, 3-hydroxykynu-renine and quinolinic acid content of mouse cerebral cortex. — Brain Res. — 1989. — V.491. — P. 173-179.

Heyes M. P., Rubinow D., Lane C., Markey S. P. Cerebrospinal fluid quinolinic acid concentration are increased in acqired immune deficiency syndrome. Ann. Neurol. — 1989. — V.26. — P. 275-277.

Heyes M. P., Saito K, Crowley J. et al. Quinolinic acid and kynurenine pathway metabolism in inflammatory and noninflammatory neurologic disease. — Brain. — 1992. — V. 115. — P. 1249-1273.

Heyes M. P., Saito K., Lackner A et al. Sources of the neurotoxin quinolinic acid in the brain of HIV-l-infected patients and retrovi-rus-infected macaques. — FASEB J. — 1998. — V. 12. — P. 881-896.

Heyes M. P., Saito K., Devinsky O. Nadi N. S. Kynurenine pathway metabolites in cerebrospinal fluid and serum in complex partial seizures. — Epilepsia. — 1994. — V. 35. — P. 251-257.

Heyes M. P., Saito K, Major E. O. et al. A mechanism of quinolinic acid formation by brain in inflammatory neurologic disease. Attenuation of synthesis from 1-tryptophan by 6-chlorotryptop-han and 4-chloro-3-hydroxyanthanilate. — Brain. — 1993. — V. 116. -P. 1425-1450.

Heyes M. P., Saito K, Markey S. P. Human macrophages convert L-tryptophan to the neurotoxin quinolinic acid. Biochem. J. -1992. -V. 283. -P. 633-635.

Heyes M. P., Saito K, Milstien S., Schiff S. J. Quinolinic acid in tumors, hemorrhage and bacterial infections of the central nervous system in children. — J. Neurol. Sci. — 1995. — V. 133. — P. 112-118.

Heylinger S. O., Mazzio E. A, Soliman К F. A — The antiinflammatory effects of quinolinic acid in the rat. — Life Sci. — 1999. — V. 64. -No. 14.-P. 1177-1188.

Hidaka H., Shoka F., Hashizume Y., Jakemoto N.. Yamamoto M. Inhibition of dopamine-p-hydroxylase in blood vessels by picoli-nic acid derivatives in vivo and their antihypertensive effects. — Japan. J. Pharmacol. — 1975. — V. 25. — P. 515-524.

Hidaka H., Shoka F., Hashizume Y., Takemoto N., Yamamoto M. Inhibition of dopamine-p-hydroxylase by picolinic acid derivatives in vivo and their antihypertensive effects. — Japan. J. Pharmacol. -1975.-V. 25.-P. 515-524.

Higgins G. A., Le A. D., Sellers E. M. 5-HT mediation of alcohol self-administration, tolerance and dependence: pre-clinical studies. -The Pharmacology of Alcohol Abuse (ed. Kranzler H. R). — Chapter &. — Berlin. — Springer. — 1995. — P. 139-168.

Hlinak Z., Krejci I. Kynurenic acid and 5,7-dichlorkynurenic acids improve social and object recognition in male rat. — Psychop-harmacology. — 1995. -V. 120. — P. 463-467

Hodgkins P. S., Schwarcz R. Metabolic control of kynurenic acid formation in the rat brain. — Developmental Neurosciaence. -1998.-V. 20.-P. 408-416.

Hoffman P. L. Effect of alcohol on excitatory amino acid receptor function. — The Pharmacology of Alcohol Abuse (ed. Kranzler H. R) — Chapter 4. — Berlin. — Springer. — P. 75-102.

Holmes S. W., Sugden D. Effects of melatonin on sleep and neurochemistry in the rat. — Brit. J. Pharmacol. — 1982. — V. 76. -P. 95-101.

Holscher C., Schmidt W. J. Quinolinic acid lesion of the rat en-tothinal cortex pars medialis produces selective amnesia in allocent-ric working memory (WM), but not in egocentric WM. — Behavioral Brain Res. — 1994. — V. 63. — P. 187-194.

Hoes M. J., Sijben N. The clinical significance of disordered renal excretion of xanthurenic acid in depressive patients. — Psychop-harmacology. — 1981. — V. 75. — P. 346-349.

Hughes R. N. Drugs which induce anxiety: caffeine. New Zeal. J. Psychol. — 1996. — V. 25. — P. 36-42.

Huidobro F., Contreras E., Crozatto R. Studies on morphine. III. Action of metabolic precursors of serotonin and noradrenaline and related substances on the «abstinence syndrome» to morphine on white mice. — Arch. int. pharmacodyn. — 1963. -V. 146. -p. 444-454.

Hyos M. A., Carballo M. A., Cabezas R. T. et al. Relationship between methoxyindole and kynurenic pathway metabolites in plasma and urine in children suffering from febrile and eplieptic seizures. — Clin. Endocrinology. — 1997. — V.47. — P. 667-678.

Ichichara К., Suzuki Т., Suda M. et al. (Eds.) Tryptophan metabolism. — A Tanabe amino acid research foundation symposium. -Sekai Hoken Tsushinsha Ltd. — Osaka. — 1964. — V. 1.

Ishiguro S., Miyao N. Влияние хлорида лития на активность триптофаноксигеназы печени крыс. Кагосима дайгаку ногакубу гакудзюцу хококу (Bull. Fac. Agr. Kagoshima Univ. Japan). -1980. -No. 30. P. 193-199. — цит. по РЖ Биохимия. — 1981. — 24537.

Ito M., Oguro K, Tsuda H. et al. Role of N-methyl-D-aspartate receptor in seizures of EL mice. — Epilepsia. — 1991. — V. 32. Suppl.l. — P. 60.

Itoh J., Nabeshima Т., Kameyama T. Utility of an elevated plus-maze for the evaluation of memory in mice: effects of nootropics, scopolamine and electroconvulsive shock. — Psychopharmaco-logy. — 1990. — V. 101. — P. 27-33.

Izumi K, KojaT., ShimizuT., Chikara K, FukudaT. Inhibitory action of taurine against experiemntal epilepsies: specificity and mechanisms. — Jap. J. Pharmacol. — 1982. — V. 32. — Suppl. P. 26. -цит. по РЖ Фармакол. — 1983. — 6.54.249

Jahamandas К H., Boegman R. J., Beninger R J., Flescher S. Role of zinc in blockade of excitotoxic action of quinolinic acid by picolinic acid. — Amino Acids. — 1998. — V. 14. — P. 257-262.

Jahamandas К H., Cockhill J, Boegman R J., Beninger R. J. Modification of quinolinic acid-induced excitotoxicity by certain pyridine monocarboxylic and dicarboxylic acids. — Eur. J. Pharmacol. -1990.-V. 183.-P. 962.

Jauch D. A., Sethy V. H., Weick B. G., ChaseT. N., Schwarcz R. Intravenous administration of L-kynurenine to Rhesus monkeys -Effect on quinolinate and kynurenate levels in serum and cerebrospinal fluid. — Neuropharmacology. — 1993. -V. 32. — P. 467-472.

Johnson M. D., Carroll B. L., Whetsell W. O.jr., Crowley W. R. Quinolinic acid stimulates luteinizing hormone through a se-rotonin-dependent mechanism. — Exp. Brain Res. — 1985. — V. 59. —P. 62.

Johnson М. D., Whetsell W. О. jr., Crowley W. R Quinolinic acid stimulates luteinizing hormone secretion in female rats: evidence for involvement of N-methyl-D-aspartate-preferring receptors. -Exp. Brain Res. — 1985. — V. 59. — P. 57.

Johnston G.A. R Convulsions induced in 10-day-old rats by intraperitoneal injection of monosodium glutamate and related excitant amino acids. — Biochem. Pharmacol. — 1973. — Y.22. -P. 137-139.

Joseph M. H. The determination of kynurenine by gas-liquid chromatography; evidence for its presence in rat brain. — Brit. J. Pharmacol. — 1977. — V. 59. — 525P.

Joseph M. Brain tryptophan metabolism on the 5-hydroxytryp-tamine and kynurenine pathways in a strain of rats with a deficiency in platelet 5-HT. — Brit J. Pharmacol. — 1978. — V. 63. — P. 529-533.

Joseph M. Determination of kynurenine by a simple gas-liquid chromarographic method applicable to urine, plasma, barin and cerebrospinal fluid. — J. Chromarography. — 1978. -V. 146. — P. 33-41.

Joseph M. Mechanism of decline in rat brain 5-hydroxytrypta-mine after induction of liver tryprophan pyrrolase by hydrocortisone: roles of tryptophan catabolism and kynurenine synthesis. — Brit. J. Pharmacol. — 1981. -V. 74. — P. 695-700.

Joseph M. H., Baker H. F., CrowT. J., Riley G. J., Risby D. Brain tryptophan metabolism in schizophrenia: a post mortem study of metabolites on the serotonin and kynurenine pathways in schizophrenic and control subjects. — Psychopharmacology. -1979. — V. 62. -P. 279-285.

Joseph M. H., Baker H. F., Lawson A. M. Positive identification of kynurenine in rat and human brain. — Biochem. Soc. Transactions. — 1978. — V. 6. — P. 123-126.

Joseph M. H., Kadam В. V., Whitaker P. M. Central interaction of kynurenine and serotonin: direct or indirect? — Current Aspects of Neurochemistry and Function (Proc. Int. Soc. Neurochem. Symp., Athens, 11-16 Sept., 1979). — цит. по РЖ Физиол. -1984. — 5 П188.

Joseph M. H., Risby D. The determination of kynurenine in plasma. — Clinica Chimica Acta. — 1975. — V. 63. — P. 197-204.

Joseph M. H., Young S. N. Curzon G. The metabolism of tryptophan load in rat brain and liver. The influence of hydrocortisone and allopurinol. — Biochem.Pharmacol. — 1976. -V. 25. -P. 2599-2604.

Joung S. N., Joseph M. H., Gauthier S. Studies on kynurenine in human cerebrospinal fluid: lowered level in epilepsy. — J. Neural Transmission. — 1983. — V. 58. — № 3-4. — P. 193-204.

Jouvet M. Biogenic amines and the states of sleep. — Science. -1969.-V. 163. — P.32-41.

Keilhoff G., Wolf G., Statny F. Effects of MK-801, ketamine and alaptide on quinolinate models in the maturing hippocampus. — Ne-urosci. — 1991. — V. 42. — P. 379-385.

Kennet G. A, Joseph M. H. The functional importance of increased brain tryptophan in the serotonergic response to restrained stress. — Neuropharmacology. — 1981. -V. 20. — P. 39-43.

KentT. A, Campbell I. L., PazdernikT. L., Hunter R., Gunn W., GoodwinD.W. — Blood platelet uptake of serotonin in men alcoholics. — J. Stud. Alcohol. — 1985. — V. 46. — P. 357-359.

Kerr S. J., Armati P. J., Guillemin C. J., Brew B. J. I. Chronic exposure of human neurons to quinolinic acid results in neuronal changes consisted with AIDS dementia complex. — AIDS. — 1998. -V. 12. — P. 355-364.

Kerr S. J., Armati P. J., Pemberton C. A et al. Kynurenine pathway inhibition reduces neurotoxicity of HIV-l-infected macrophages. — Neurology. — 1997. — V. 49. — P. 1671-1681.

Kiely M., Sourkes T. L. Transport of L-trypophan into slices of rat cerebral cortex. — J Neurochem. — 1972. — V. 19. — P. 2863.

Kim J. P., Choi D. W. Quinolinate neurotoxicity in cortical cell culture. Neuroscience. — 1987. -V. 25. — P. 423-432.

Kim J. P., Koh J., Choi D. W. L-homocysteate is a potent neurotoxin on cultured cortical neurons. — Brain Res. — 1987. — V. 437. -P. 103-110.

Ют J. H., Miller L. L. The functional significance of changes in activity of the enzymes tryptophan pyrrolase and tyrosine transaminase, after induction in intact rats and in the isolated perfused rat liver. — J. Biol. Chem. — 1969. — V. 244. — P. 1410-1416.

Kirkegaard C., Moller S. E., Bjorum N. Addition of L-trytophan to electroconvulsive treatment in endogenous depression. A doub-le-blind study. — Acta Psychiatrica Scandinavica. — 1978. — V. 58. -P. 457-462.

KitaT., Kamiya H., Kiyota C. Effect of intraventricular injection of N-methylated GABA-derivatives on the central nervous system of conscious mice. — Biochem. Pharmacol. -1963. — V. 12. -P. 2134-214.

Kitt Т. M., Spector R. Transport of quinolinic acid into rabbit and rat brain. — Neurochem. Res. — 1987. — V. 12. — P. 625-628.

Klerman G. L. Stress, adaptation and affective disorders. -Stress and Mental Disorder (eds. Barrett J. E., Rose R. M., Юег-man G. L.). — Raven Press. — New York. — 1979. — P. 151-160.

Klitgaard H. N-methyl-D-aspartate antagonists and strychi-nie-insensitive glycine site antagonists: effect on NMDA-induced convulsions after different routes of administration. — Epilepsia. -1991. — V. 32. — Suppl. 1. — P. 46-48.

Komrower G. M., Wilson V., Clamp J.R et al. Hydroxykynureni-nuria. — Arch. Dis. Childh. — 1964. — V. 39. — P. 250-256.

Konig J., Klippel R. A. The rat brain. A stereotaxic atlas of the fo-rebrain and lower parts of the brain stem. — Willians and Wilkins Co. -Baltimore. — 1963. — 182 p.

Koob G. F., Mendelson W. В., Schafer J. et al. Picrotoxin receptor ligand blocks antipunishment effects of alcohol. — Alcohol. -1988. — V. 5. — P. 437-443.

Kozilkowski A. P. (Ed.) Neurobiology of the NMDA receptor. From Chemistry to the Clinic. VCH Publ. Inc. — New York. -1991. -250 p.

Kranzler H. R. (ed.) The pharmacology of Alcohol Abuse. -Handbook of Expreimnetal Pharmacology. — V. 114. — Berlin. -Springer. — 1995. — 548 p.

Kretschmer B. D., Bubser M., Schmidt W. J. Behavioral and neurochemical actions of the strychnine-insensitive glycine receptor antagonist, 7-chlorokynurenic acid, in rats. — Eur. J. Pharmacol. -1995.-V. 280.-P. 37-46.

Kretschmer B. D., Winterscheid В., Danysz W., Schmidt W. J. Glycine site antagonsists abolish dopamine D2 but not D1 receptor mediated catalepsy in rats. — J. Neural Transmission. -1994. -V. 95. — P. 123-136.

Krieger C., Hansen S., Heyes M. P. Amyotrophic lateral sclerosis: quinolinic acid levels in cerebrospinal fluid and spinal cord. -Neurodegeneration. — 1993. — V. 4. — P. 237-242.

Kuhs H. Anxiety and depressive disorders. Comprehensive Psychiatry. — 1991. -V. 32. — P. 217-228.

Kvetnoy I. M., Reiter R. J. (eds.) Melatonin: general biological and oncoradiological aspects. — Obninsk. — Med. Radiol. Res. Center, Russian Academy of Med. Sci. — 1994. — 82 p.

Labadarios D., McKenzie D. Y., Dickerson J. W.T., Parke D. V. Metabolic abnormalities of tryptophan and nicotinic acid with rheumatoid arthritis. — Rheumat and Rehabil. -1978. — V. 17. -P. 227-232.

Lange J., Rump S., Ilczuk I. et al. Synthesis and properties of cyclic derivatives of succinic acid with anticonvulsant activity. -Pharmazie. — 1979. — Bd. 34. — S. 794-795.

Lapin I. P. Neurotropic activities of kynurenine and its metabolites. — First Congress of the Hungarian Pharmacological Society (Abstracts of the papers). — Budapest. — 1971. — P. 127.

Lapin I. P. Interaction of kynurenine and its metabolites with tryptamine, serotonin and its precursors and oxotremorine. — Psyc-hopharmacologia. — 1972. — V. 26. — P. 237-247.

Lapin I. P. Neurotropic activities of kynurenines and its metabolites. — Symposium on Pharmacological Agents and Biogenic Amines in the Central Nervous System (eds. Knoll J., Magyar K.) -Akademiai Kiado. — Budapest. — 1973. — P. 149-164.

Lapin I. P. Kynurenines as probable participants of depression. -Pharmakopsychiatrie — Neuropsychopharmakologie — 1973. — V. 6. -P. 273-279.

Lapin I. P. Antagonism of nicotinic acid and other kynurenines to antidepressants: one of probable reasons of the therapy-resistan-ce in depression?-Activitas nervosa superior (Praha). — 1974. -V. 16. — P. 260-261.

Lapin I. P. Kynurenines and effects of amphetamine and apo-morphine. — Second Congress of the Hungarian Pharmacological Society (Abstracts of the papers). — Budapest. — 1974. — P. 3/39.

Lapin I. P. Depressor effect of kynurenine and its metabolites in rats. — life Sciences. — 1976. — V. 19. — No. 10. — P. 1479-1484.

Lapin I. P. Stimulant and convulsive effects of kynurenines injected into brain ventricles in mice. — J. Neural Transmission. -1978.-V. 42.-P. 37-43.

Lapin I. P. Convulsions and tremor in immature rats after intraperitoneal injection of kynurenine and its metabolites. — Pharmacol. Res. Communications. — 1978. — V. 10. — P. 81-84.

Lapin I. P. Kynurenines and ethanol intoxication and withdrawal in mice. — 32nd Int. Congress on Alcoholism and Drug Dependence (Warsaw, 3-8 September, 1978). Abstracts of the papers. Warsaw. — 1978. V. 1. — P. 40.

Lapin I. P. Kynurenines and audiogenic excitement in mice. -Pharmacology Biochemistry Behavior. — 1980. — V. 13. — P. 9-15.

Lapin I. P. Effect of kynurenine and quinolinic acid on the action of convulsants in mice. — Pharmacology Biochemistry Behavior. -1980. V. 13. — P. 17-20.

Lapin I. P. Are kynurenines involved in epilepsy? — 35th Annual Convention of the Society of Biological Psychiatry (Boston, September 5-7,1980). — 1980. — P. 78.

Lapin I. P. Taurine selectively antagonizes L-kynurenine-pro-duced seizures in mice — J. Neural Transmission. — 1980. — V.48. -P. 311-316.

Lapin I. P. Experimental studies on kynurenines as neuroactive tryptophan metabolites: past, present, future. — Trends in Pharmacol. Sciences. — 1980. — V. 1. — P. 410-412.

Lapin I. P. Antagonism of glycine to seizures induced by L-ky-nurenine, quinolinic aicd and strychnine in mice. — Eur. J. Pharmacol. — 1981a. — V. 71. — P. 495-498.

Lapin I. P. Nicotinamide, inosine and hypoxanthine, putative endogenous ligands of the benzodiazepine receptor, opposite to diazepam are much more effective against kynurenine-induced seizures than against pentylenetetrazol-induced seizures. Pharmacol.Bi-ochem. Behav. — 1981b. — V. 14. — P. 589-593.

Lapin I. P. Kynurenines and seizures (review). — Epilepsia. -1981c.-V. 22.-P. 257-265.

Lapin I. P. Convulsant action of intracerebroventricularly administered 1-kynurenine sulphate, quinolinic acid and other derivatives of succinic acid, and effects of aminoacids: structure-activity relationships. — Neuropharmacology. — 1982. -V. 21. — P. 1227-1232.

Lapin I. P. Antagonism of kynurenine-induced seizures by picoli-nic, kynurenic and xanthurenic acids. — J. Neural Transmission. -1983a.-V. 56.-P. 177-185.

Lapin I. P. Structure-activity relationships in kynurenine, diazepam and some putative endogenous ligands of the benzodiazepine receptors. — Neuroscience and Biobehavioral Reviews. — 1983b. -V. 7. — P. 107-118.

Lapin I. P. Probable involvement of kynurenine in anxiety: deterioration of the conflict situation and partial antagonism with diazepam. — Second Congress of the Bulgarian Pharmacological Society, Plovdiv, 1984. — P. 232

Lapin I. P. Experimental therapy of seizures induced by endogenous convulsants 1-kynurenine and quinolinic acid. — Neuropsyc-hopharmacology-85 (eds. Kelemen K., Magyar K., Vizi E. S.). — Publ. House of the Hungarian Academy of Sciences. — Budapest. — 1985a. -P. 237-240.

Lapin I. P. Endogenous antagonists of quinolinic acid and kynurenine as links of the defensive mechanism in epilepsy. Acta Neuro-logica. — 1985b. — New Series ((XL). — No. 3/4. — P. 203-206.

Lapin I. P. Kynurenines and behavior. — Frontiers in Excitatory Amino Acids Research (Eds. Cavalheiro E. A., Lehmann J., Turs-ki L.). Alan R. Liss. — New York. — 1988. — P. 605-611.

Lapin I. P. Behavioral and convulsant effects of kynurenines (Chapter) Quinolinic Acid and Kynurenines (Ed. Stone T. W.). -CRC Press. — Boca Raton. — 1989. — P.193-211.

Lapin I. P. Anxiogenic effect of phenylethylamine and amphetamine in the elevated plus-maze in mice and its attenuation by ethanol. — Pharmacology Biochemistry Behavior. — 1993. — V. 44. — P. 241-243.

Lapin I. P. Kynurenines as putative endogenous anxiogens and anxiolytics. — Pharmacology and Toxicology. — 1995. — V. 76. -Suppl. III. P. 42.

Lapin I. P. Kynurenines and anxiety. — Recent Advances in Try-tophan Research. Tryptophan and Kynurenine Pathways. (Eds. Fi-lippini G. A, Costa C. V.L., Bertazzo A.). — Plenum Press. — New York-London. — 1996a. — P. 191-194.

Lapin I. P. Putative endogenous anxiogens and anxiolytics. -Biol. Psychiatry. — 1996b. — V. 39. — P. 563-564.

Lapin I. P. Antimuscarinics-sensitive and insensitive dopaminergic excitation induced by NMDA antagonists (comparison with amphetamine and diazepam) and serotoninergic hyperactivity induced by ethanol. — «Neurochemistry and Pharmacology of Drug Addiction», Int. Conference (St. Petersburg, June 8-10, 1996). Abstracts. — 1996c. — P. 12-13.

Lapin I. P. Lowered serotonin uptake in blood platelets in alcoholic patients. Is it specific for alcoholism? Does it appear before or during the disease? — Alcohol and Alcoholism. — 1997a. -V.32. -P. 383.

Lapin I. P. Kynurenines and alcoholism. — Biol. Psychiatry. -1997b. — V. 42. — No. IS. — P. 18S.

Lapin I. P. Quinolinic acid — monoamine oxidase В — phenylet-hylamine- anxiety. — J. Neurochemistiy. — 1998. -V. 71. — Suppl. 1. -P. 35.

Lapin I. P. Antagonism of kynurenic acid to anxiogens in mice. -Life Sci. (Pharmacology Letters). — 1998a. — V. 63. — PL31 — PL.36.

Lapin I. P. The three foundation stones of the laboratory of psychopharmacology. — In: The Rise of Psychopharmacology and the story of CINP (eds. BanT. A, Healy D., Shorter E.). — Animula. -Budapest. — 1998b. — P. 323-329.

Lapin I. P. The most informative predictive effects of anxiogens and anxiolytics in three standard models of anxiety (dark-light chamber, elevated plus-maze, social interaction test). — Eur. Neu-ropsychopharmacology. — 2000. — V. 10. Suppl. 2. — P. 65-66.

Lapin I. P. The Neuroactivities of Kynurenines: Stress, Anxiety, Depression, Alcoholism, Epilepsy (The 2000 Oswald Schmiedeberg Lecture). — Tartu. — Tartu University Press. — 2000. — 32 p. (124 ref.).

Lapin I. P., Jagiello-Wojtowicz E. Kynurenines antagonism against 5-HTP-potentiated action of imipramine and amitriptyline in frogs. — Acta physiol. polonica. — 1976. — V. 27. — P. 591-594.

Lapin I. P., Kozlovsky V. L., Kenunen O. G. Behavioral abnormalities in rats after single treatment with quinolinic acid during early ontogenesis. — In: Kynurenine and serotonin pathways (Progress in Tryptophan Research), ed. by Schwarcz R, Young S. N., Brown S. N. Plenum Press. — N.Y.-London. — 1991. — P. 337-342.

Lapin I. P., Mirzaev S. M., Oxenkrug G. F., Ryzov I. V. Anticonvulsant activity of melatonin against seizures induced by quinolinate, kainate, glutamate, NMDA, and pentylenetetrazole in mice. -J. Pineal Research. — 1998. — V. 24. P. 215-218.

Lapin I. P., Mirzaev S., Ryzov I. V. Endogenous antagonists of the convulsant effect of quinolinic acid. — Polish J. Pharmacol. -1995. — V. 47. — Suppl. — P. 18-19.

Lapin I. P., Mutovkina L. G., Ryzov I. V., Mirzaev S. Anxiogenic activity of quinolinic acid and kynurenine in the social interaction test in mice. — J. Psychopharmacology. — 1996. -V. 10. — P. 246-249.

Lapin I. P., Oxenkrug G. F. Intensification of the central seroto-ninergic processes as a possible determinant of the thymoleptic effect. Lancet. — 1969, January 18. — 132-136.P.

Lapin I. P., Politi V. Anxiolytic effect of indole-3-pyruvic acid (IPA) in mice. — Pharmacol. Research. -1993. — V. 28. — P. 129-134.

Lapin I. P., Politi V. Antiethanol effects of indole-3-ylpyruvic acid in mice. — Alcohol and Alcoholism — 1994. — V. 29. — P. 265-268.

Lapin I. P., Prakhie I. В., Kiseleva I. P. Excitatory effects of kynurenine and its metabolites, amino acids and convulsants administered into brain ventricles: differences between rats and mice. -J. Neural Transmission. — 1982. — V. 54. P. 229-238.

Lapin I. P., Prakhie I. В., Kiseleva I. P. Antagonism of seizures induced by the administration of the endogenous convulsant quinolinic acid into rat brain ventricle. — J. Neural Transmission. — 1986. -V. 65. — P. 177-186.

Lapin I. P., Rogawski M. A Muscarinic antagonists attenuate di-zocilpine-induced hypermotility in mice. — Life Sci. — 1992. — V. 50. -PL 59-P1.64.

Lapin I. P., Rogawski M. A. Effect of D1 and D2 dopamine receptor antagonists and catecholamine depleting agents on the locomotor stimulation induced by dizocilpine, d-amphetamine and diazepam. — Behavioral Brain Res. — 1995. — V. 70. — P. 145-151.

Lapin I. P., Ryzov I. V. Effects of catecholaminergic drugs on quinolinate- and kynurenine-induced seizures in mice. — J. Neural Transmission. — 1990. — V. 82. — P. 55-65.

Lavaggi M. V., Politi V., De Luca G., Gorini A. Effects of indo-le-pyruvic acid on tryptophan pyrolase activity in vitro and in vivo. —Progress in Tryptophan and Serotonin Research (eds. Bender D. A., Joseph M., Kochen W., Steinhart H.) — Walter de Gruyter & Co. -Berlin-New York. — 1987. — P. 51-54.

Lazarova M., Roussinov K. On some relationships between dopaminergic and serotoninergic mechanisms in pentylenetetrazol convulsions in albino mice. — Acta Physiol. Pharmacol. Bulg. -1979. -V. 5. — P. 67-74.

Lazarova M., Samanin R. Serotonin mediation of the protective effect of clonidine against pentylenetetrazol-induced seizures in rat. -Life Sci. — 1983. — V. 32. — P. 2343-2348.

Lee C., Rodgers R. J. Effects of buspirone on antinoceceptive and behavioral responses to the elevated plus-maze in mice. — Be-hav. Pharmacol. — 1991. — V.2. — P. 491-496.

Leib S. L., Kim Y. S., Ferriero D. M.( Tauber M. G. Neuroprotective effect of excitatory amino acid antagonist kynurenic acid in expreimental bacterial meningitis. — J. Infect. Dis. -1996. -V. 173. -P. 166-171.

Leibenluft E., Madden P. A., Dick S. E., Rosenthal N. E. Primary depressives with secondary alcoholism compared with alcoholics and depressives. — Comprehensive Psychiatry. — 1993. — V. 34. -P. 83-86.

Lekieffre D., Ghibri О., Callebert J et al. Inhibition of glutamate release in the rat hippocampus by kynurenic acid does not protect CA1 cells from forebrain ischemia. Brain Research. -1992. -V. 592. -P. 333-337.

Leklem J. E., Brown R. R., Hankes L. V. et al. Tryptophan metabolism in the cat: a study with carbon-14-labeled compounds. Amer.J. Vet. Res. — 1971. — V. 32. — P. 335-344.

Leon J., Vives F., Crespo E. et al. Modification of nitric oxide synthase activity and neuronal response in rat striatum by melatonin and kynurenine derivates. — J. Neuroendocrinology. — 1998. -V. 10. — P. 297-302.

Leuris M. R., Gallagher J. P., Shinnick-Gallagher P. An in vitro brain slice preparation to study the pharmacology of central vestibular neurons. — J. Pharmacol. Methods. — 1987. — V. 18. — P. 267-273.

Leyton M., Ghadirian A. M., Young S. N., Palmour R. M., Bli-er P., Helmers K. F., Benkelfat C. Depressive relapse following acute tryptophan depletion in patients with major depressive disorder. -J. Psychopharmcol. — 2000. — V. 14. — P.284-289.

Liebman J. M., Bennettt D. A. Anxiolytic actions of competitive N-methyl-D-aspartate receptor antagonists: a comparison with benzodiazepine modulators and dissociative anesthetics. — Frontiers in excitatory amino acid research (eds. Cavalheiro E. A., Leh-mannj. L., Tuski L.).-Alab R. Liss Inc. — New York. — 1988.-P. 301-308.

Liljequist S., Ossowska K., Grabowska-Anden M., Anden N.-E. Effect of the NMDA receptor antagonist, MK-801, on locomotor activity and on the metabolism of dopamine in various brain areas of mice. -Eur. J. Pharmacol. — 1991. — V. 195. — P. 55-61.

Linzen B. The tryptophan-ommochrome pathway in insects. -Adavances in Insect Physiology. — V. 10. — Academic press. — London. -1974. P. 117-246.

Lipska В. К, Weinberger D. R. Neonatal excitotoxic damage of the hippocampus in the rat stimulates behavioral aspects of schizophrenia. -XXIst CINP Congress (Glasgow, July 1998). — Abstracts. -P. 85.

lister R. G. The use of a plus-maze to measure anxiety in the mouse. — Psychopharmacology. — 1987. — V. 92. — P. 180-185.

little H. J., Butterworth A. R., Ocollaghan M. J., Wuilson J., Cole J., Watson W. P. Low alcohol preference among the «high alcohol preference» C57 strain of mice: preference increased by saline injections. — Psychopharmacology. — 1999. — V. 147. — P. 182-189.

Loscher W., Ebert U., Lehmann H. Killing induces a lasting regionally selective increase of kynurenic acid in the nucleus accum-bens. — Brain Res. — 1996. — V. 725. — P. 252-256.

Loscher W., Honack D. The behavioral effects of MK-801 in rats: involvement of dopaminergic, serotonergic and noradrenergic systems. — Eur. J. Pharmacol. — 1992. — V. 215. — P. 199-208.

Lou G. L, Pinsky C., Sitar D. S. Kynurenic acid distribution into brain and peripheral tissues of mice. — Canadian J. Physiol. Pharmacol. — 1994. — V. 72. — P. 161-167.

Luthman J. Neuroactive tryptophan metabolites: focus on kynurenines — Introduction. Amino Acids. -1998. — V. 14. — P. 241-242.

К комментариям в ЖЖ

Добавить комментарий

Ваш адрес email не будет опубликован. Обязательные поля помечены *